A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Adjuvant Melanoma Stakeholder Treatment Preference Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05115006

Enrollment

294

Registered

2021-11-10

Start date

2021-01-07

Completion date

2022-06-02

Last updated

2022-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Keywords

Melanoma, Discrete choice experiment, Resected melanoma, Adjuvant treatment, Patient preference

Brief summary

The purpose of this study is to understand the trade-offs that participants with surgically treated melanoma would be willing to make among key features and outcomes of adjuvant anti-cancer treatments or no adjuvant treatment / observation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Self-reported medical diagnosis of stage II or stage III melanoma * Have been resected (had surgery) for their melanoma within 12 months prior to study participation

Exclusion criteria

* Self-reported stage IIa * Self-reported recurrence of melanoma after surgery Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Preference weights or utilities (a measure of relative preference; on a continuous variable scale) for each treatment attribute level based on responses to the Discrete Choice Experiment (DCE) choice tasks	At Baseline

Countries

Australia

Outcome results